Recent Material Events - Durect Cp (DRRX)

Filing Date	Description
2008-12-11	Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ...
2008-10-29	A copy of DURECT’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. ...
2008-09-30	Under the amended Officer Policy, the timing of cash payments under the Officer Policy was changed in order to avoid the imposition of potential additional taxes on such payments under Section 409A. The Officer Policy now provides that payments under ...
2008-09-23	Under the terms of the agreement, upon closing of the transaction, Alpharma will pay the Company an upfront license fee of $20 million, with possible additional payments of up to $93 million upon the achievement of predefined development and regulato ...
2008-09-17	Under the amendment, among other changes, the scope of the license was broadened from the treatment of back pain to all uses covered by the EpiCept intellectual property including myofascial pain and muscle tension pain, and the license was converted ...
2008-06-30	Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ...
2008-06-17	Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ...
2008-06-11	On June 10, 2008, DURECT Corporation, a Delaware corporation (“ DURECT ”), issued a press release announcing that a New Drug Application (NDA) for Remoxy™ (ORADUR™-based oxycodone) has been submitted to the U.S. Food and Drug Admi ...
2008-01-22	$ 452,907.00 $ 183,319.50 175,000 Felix Theeuwes, D. Sc., Chairman & Chief Scientific Officer ...
2007-12-18	Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ...